

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

**PROGRESS ANNOUNCEMENT -
ESTABLISHMENT OF JV IN RELATION TO
STRATEGIC COLLABORATION ON
INNOVATIVE SURGICAL ROBOTIC SOLUTION**

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Company.

Reference is made to the announcement of the Company dated 3 April 2019 (the “**Announcement**”) in relation to the entering of a strategic collaboration agreement to establish a joint venture to focus on the R&D and commercialization of innovative surgical robotic solutions in China. Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Board announces that on 21 June 2019, the Company, through its wholly controlled subsidiary, Lifetech Scientific (Shenzhen) Co., Ltd (“**Lifetech Shenzhen**”), entered into a shareholders agreement (the “**Shareholders Agreement**”) with Quantum Surgical and ABG, in relation to the further cooperation detail on Innovative Surgical Robot to promote the R&D and commercialization of the Innovative Surgical Robot. As at the date of this announcement, the JV, namely Dongguan LifeTech-Quantum Medical Technology Co., Ltd. (“**LifeTech-Quantum**”) has been set up.

Pursuant to the Shareholders Agreement, Lifetech Shenzhen, Quantum Surgical and ABG shall hold 50.1%, 40% and 9.9% interest in LifeTech-Quantum respectively.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, Quantum Surgical and ABG are third parties independent of the Group and connected persons of the Group.

The entering of the Shareholders Agreement and furthering of the establishment of Lifetech-Quantum, the JV, shall leverage on the technological advantages, online platforms and capital support of the parties thereof, so as to promote and accelerate the acquisition of permission to launch in the Chinese market and the commercialization arrangements of the Innovative Surgical Robot, thus benefits cancer patients in China.

As all the applicable percentage ratios (as defined under the Listing Rules) in respect of the capital contribution are less than 5%, the entering into of the Shareholders Agreement does not constitute a notifiable transaction for the Company under Chapter 14 of the Listing Rules.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Chairman, Chief Executive Officer
and Executive Director*

Hong Kong, 26 June 2019

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.